J. Fyrwald Biography and Net Worth

Director of Eli Lilly and Company

J. Erik Fyrwald joined International Flavors & Fragrances Inc. in February 2024 as chief executive officer and a member of its board of directors. Previously, he served as president and chief executive officer of Syngenta from June 2016 until December 2023. He was elected to the Eli Lilly and Company board of directors in 2005.

Fyrwald served as chief executive officer of Univar from May 2012 until May 2016. In 2008, following a 27-year career at DuPont, he joined Nalco Company, serving as chairman and chief executive officer until 2011, when Nalco merged with Ecolab Inc. Following the merger, Fyrwald served as president of Ecolab.

From 2003 to 2008, Fyrwald served as group vice president of the agriculture and nutrition division at E.I. du Pont de Nemours and Company. From 2000 until 2003, he was vice president and general manager of DuPont’s nutrition and health business.

Fyrwald attended the University of Delaware, where he received a Bachelor of Science in chemical engineering in 1981. He also completed the advanced management program at Harvard Business School.

What is J. Erik Fyrwald's net worth?: The estimated net worth of J. Erik Fyrwald is at least $75.45 million as of August 12th, 2025. Mr. Fyrwald owns 74,578 shares of Eli Lilly and Company stock worth more than $75,453,546 as of December 4th. This net worth estimate does not reflect any other investments that Mr. Fyrwald may own. Learn More about J. Erik Fyrwald's net worth.
How do I contact J. Erik Fyrwald?: The corporate mailing address for Mr. Fyrwald and other Eli Lilly and Company executives is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. Eli Lilly and Company can also be reached via phone at (317) 276-2000 and via email at [email protected]. Learn More on J. Erik Fyrwald's contact information.
Has J. Erik Fyrwald been buying or selling shares of Eli Lilly and Company?: J. Erik Fyrwald has not been actively trading shares of Eli Lilly and Company during the past quarter. Most recently, on Tuesday, August 12th, J Erik Fyrwald bought 1,565 shares of Eli Lilly and Company stock. The stock was acquired at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the transaction, the director now directly owns 74,578 shares of the company's stock, valued at $47,903,686.74. Learn More on J. Erik Fyrwald's trading history.
Who are Eli Lilly and Company's active insiders?: Eli Lilly and Company's insider roster includes Anat Ashkenazi (Sr. VP & CFO ), Melissa Barnes (SVP), Enrique Conterno (SVP), Stephen Fry (SVP), J. Fyrwald (Director), Michael Harrington (VP), Jamere Jackson (Director), Susan Mahony (SVP), Johna Norton (EVP), Myles O'Neill (SVP), Derica Rice (EVP), David Ricks (CEO), Marschall Runge (Director), Aarti Shah (SVP), Christi Shaw (SVP), Jeffrey Simmons (SVP), Daniel Skovronsky (SVP), Joshua Smiley (CFO), Gabrielle Sulzberger (Director), Jackson Tai (Director), Jacob Van Naarden (Sr. VP), Alonzo Weems (EVP), Anne White (SVP), Ilya Yuffa (SVP), Donald Zakrowski (CAO), and Alfonso Zulueta (SVP). Learn More on Eli Lilly and Company's active insiders.
Are insiders buying or selling shares of Eli Lilly and Company?: In the last year, Eli Lilly and Company insiders bought shares 5 times. They purchased a total of 4,514 shares worth more than $2,894,841.15. In the last year, insiders at the sold shares 1 times. They sold a total of 1,000 shares worth more than $818,240.00. The most recent insider tranaction occured on August, 12th when CEO David A Ricks bought 1,632 shares worth more than $1,052,264.64. Insiders at Eli Lilly and Company own 0.1% of the company. Learn More about insider trades at Eli Lilly and Company.
Information on this page was last updated on 8/12/2025.

J. Erik Fyrwald Insider Trading History at Eli Lilly and Company

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/12/2025	Buy	1,565	$642.33	$1,005,246.45	74,578

J. Erik Fyrwald Buying and Selling Activity at Eli Lilly and Company

Eli Lilly and Company Company Overview

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Today's Range

Now: $1,011.74

$1,007.18

$1,032.63

50 Day Range

MA: $913.15

$724.73

$1,109.09

2 Week Range

Now: $1,011.74

$623.78

$1,111.99

Volume

3,853,037 shs

Average Volume

3,914,035 shs

Market Capitalization

$956.48 billion

P/E Ratio

49.50

Dividend Yield

0.58%

Beta

0.37